Key result
Candesartan cilexetil (1 mg/kg/day) significantly reduced infarct volumes by about 30% compared with controls in male Wistar rats subjected to middle cerebral artery occlusion.
Why the study?
Does candesartan cilexetil reduce infarct volume and improve neurological scores in male Wistar rats following middle cerebral artery occlusion?
Does candesartan cilexetil reduce infarct volume and improve neurological scores in male Wistar rats following middle cerebral artery occlusion?
Candesartan cilexetil demonstrates neuroprotective effects in a rat model of stroke, reducing infarct volume and improving neurological scores.
Does not support clinical use in stroke; hypothesis-generating for ARB neuroprotection in ischemia models.
Male Wistar rats were treated with an angiotensin AT1 receptor antagonist, candesartan cilexetil (TCV-116, 1 mg/kg/day) over a 4-week period. Systolic blood pressure was significantly reduced by 14% after 1 week and remained stable for the next 3 weeks compared with controls. Up-regulation of AT2, but not AT1, receptor gene expression by 3.4-fold and 5.0-fold was observed 1 and 4 weeks after treatment. Middle cerebral artery occlusion caused significantly reduced infarct volumes in TCV-116-treated rats, by about 30% when compared with control rats. Neurological scores were also improved in treated rats. These results suggest that the neuroprotective effects of TCV-116 may be mediated through AT1 receptor antagonism and AT2 receptor up-regulation.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2004) studied Middle cerebral artery occlusion. Candesartan cilexetil (TCV-116) vs. Controls was evaluated on Infarct volumes. Candesartan cilexetil (1 mg/kg/day) significantly reduced infarct volumes by about 30% compared with controls in male Wistar rats subjected to middle cerebral artery occlusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: